This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Barclays Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT)

Tipranks - Tipranks - Tue Jun 23, 3:46AM CDT

In a report released today, Eliana Merle from Barclays maintained a Hold rating on Sarepta Therapeutics, with a price target of $20.00.

TipRanks' Prime Week Sale - 70% Off

Merle covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, BridgeBio Pharma, and Ionis Pharmaceuticals. According to TipRanks, Merle has an average return of 0.7% and a 41.92% success rate on recommended stocks.

The word on The Street in general, suggests a Hold analyst consensus rating for Sarepta Therapeutics with a $22.81 average price target.

See today’s best-performing stocks on TipRanks >>

Based on Sarepta Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $730.8 million and a net profit of $330.96 million. In comparison, last year the company earned a revenue of $744.86 million and had a GAAP net loss of $447.51 million

Read More on SRPT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).